Items Tagged ‘HER2-negative’

June 7th, 2016

Abemaciclib Promising in Advanced Breast Cancer

By

The investigative agent abemaciclib, which is still in clinical trials, appears promising in providing anti-cancer activity among patients with metastatic breast cancer that has progressed following several prior therapies. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology. Metastatic breast cancer (MBC) refers to cancer that has […]

View full entry

Tags: 2016, abemaciclib, asco, Breast Cancer, HER2-negative, HR-positive, MBC, Metastatic Breast Cancer, MONARCH 1 trial, News


April 28th, 2016

Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen

By

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently published in the Journal of Clinical Oncology. The majority of breast cancers, referred to as hormone-positive breast cancers, […]

View full entry

Tags: aromasin, Breast Cancer, exemestane, HER2-negative, hormone-positive, News, premenopausal, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, tamoxifen


March 17th, 2016

Ibrance® Approved for Use in Combination with Faslodex® in Hormone-Positive Breast Cancer

By

The United States Food and Drug Administration (FDA) has approved Ibrance (palbociclib) to be used with Faslodex (fulvestrant) for women with hormone-positive (HR-positive), human epidermal growth factor receptor-2 (HER2)-negative, metastatic breast cancer that has progressed following prior endocrine (hormone) therapy. The majority of breast cancers are HR-positive. These cancers are stimulated to grow by the […]

View full entry

Tags: approval, Breast Cancer, Faslodex, fda, fulvestrant, HER2-negative, hormone-positive, Ibrance, metastatic, Metastatic Breast Cancer, News, palbociclib


December 22nd, 2015

Adding Carboplatin to Pre-surgery Chemotherapy Improves Survival for Patients with Triple-Negative Breast Cancer

By

Adding carboplatin to pre-surgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer (TNBC), according to results from a German clinical study released at the San Antonio Breast Cancer Symposia.1 Breast cancers that are not stimulated to grow from exposure to estrogen or progesterone and are HER2 (human epidermal growth factor receptor)-negative are called […]

View full entry

Tags: Breast Cancer, carboplatin, HER2-negative, News, surgery, tnbc, Triple Negative Breast Cancer


September 16th, 2015

A Vegan or Vegetarian Diet May Help Improve Treatment of Triple-Negative Breast Cancer

By

Early research suggests that a vegan or vegetarian diet low in the amino acid methionine may help improve treatment of triple-negative breast cancers. These findings were reported in the journal Clinical Cancer Research. The majority of breast cancers are hormone receptor-positive, meaning that the cancer cells are stimulated to grow from exposure to the female […]

View full entry

Tags: Breast Cancer, diet, HER2-negative, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, TRAIL-R2, treatment, triple negative, vegan, vegetarian


September 8th, 2015

Biomarker May Help Improve Treatment of Triple-Negative Breast Cancer

By

Researchers have found a biomarker that appears active in the growth and spread of triple-negative breast cancer. Known as interleukin-13 receptor alpha 2 (IL13Ralpha2), the biomarker may help doctors identify patients at high risk of disease spread and potentially provide a target for treatment. These findings were reported in Breast Cancer Research. The majority of […]

View full entry

Tags: biomarker, Breast Cancer, Carcinoma In Situ Breast cancer, HER2-negative, IL13Ralpha2, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, Triple Negative Breast Cancer


June 3rd, 2015

Combination of Ibrance® plus Faslodex® Promising in Advanced Hormone-Positive Breast Cancer

By

The combination of Ibrance® (palbociclib) and Faslodex® (fulvestrant) appears to extend progression-free survival in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER)-negative metastatic breast cancer. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the New England […]

View full entry

Tags: Breast Cancer, ER-positive, Faslodex, HER2-negative, hormone-receptor positive, Ibrance, Metastatic Breast Cancer, News